EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Liver fibrosis biomarkers as a prognostic tool beyond the defining components in cardiovascular-kidney-metabolic syndrome

Zhenyang Cao, Binyan Chen, Jinghao Zhou, Jijie Jin, Dmitry Abramov, Shengzhang Chen, Pan Huang, Jianghua Zhou

American Journal of Preventive Cardiology · 2026-04 · 26 · 101438

DOI: 10.1016/j.ajpc.2026.101438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Preventive Cardiology, 2026-04. Verfasst von Zhenyang Cao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health Commission of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the multisystem nature of Cardiovascular-Kidney-Metabolic (CKM) syndrome, hepatic dysfunction markers are rarely included. We evaluated whether two noninvasive liver fibrosis scores (LFSs)-the Fibrosis-4 Index (FIB-4) and the non-alcoholic fatty liver disease fibrosis score (NFS)-independently predict all-cause mortality (ACM) and cardiovascular mortality (CVM) in CKM, and whether they complement CKM staging to better capture mortality risk heterogeneity.

Methods

We analyzed data from the National Health and Nutrition Examination Survey (NHANES) 2005-2018 (n=32,197) and the UK Biobank (n=88,590). The least absolute shrinkage and selection operator (LASSO) selected a parsimonious covariate set for the baseline Cox model, to which FIB-4 or NFS was added separately. Incremental prognostic value was assessed by discrimination (C-index, time-dependent area under the receiver operating characteristic curve [AUC]), model fit (likelihood ratio test [LRT]), and clinical utility (decision curve analysis). We also compared the original CKM staging with a CKM-Liver staging that added an intermediate-to-high fibrosis-risk indicator.

Results

Survival declined with higher LFS, and both scores independently predicted ACM and CVM. Adding FIB-4 or NFS modestly improved discrimination and model fit (ACM ΔC-index=0.009 and 0.008; LRT P

Schlagwörter

Stichwörter der Autor:innen

Cardiovascular-Kidney-Metabolic syndromeLiver fibrosisMortalityNational health and nutrition examination SurveyUK biobank

Autor:innen und Institutionen

  • Department of Cardiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
  • School of Nursing, Wenzhou Medical University, Wenzhou, Zhejiang province, China.
  • Division of Cardiovascular Medicine, Loma Linda University Medical Center, Loma Linda, California, USA.

Förderung

  • National Health Commission of the People's Republic of China

Zitieren

APA

Cao, Z., Chen, B., Zhou, J., Jin, J., Abramov, D., Chen, S., Huang, P., & Zhou, J. (2026). Liver fibrosis biomarkers as a prognostic tool beyond the defining components in cardiovascular-kidney-metabolic syndrome. American Journal of Preventive Cardiology, 26, 101438. https://doi.org/10.1016/j.ajpc.2026.101438

Vancouver

Cao Z, Chen B, Zhou J, Jin J, Abramov D, Chen S, et al. Liver fibrosis biomarkers as a prognostic tool beyond the defining components in cardiovascular-kidney-metabolic syndrome. American Journal of Preventive Cardiology. 2026;26:101438. doi:10.1016/j.ajpc.2026.101438

BibTeX
@article{Cao2026,
  author = {Cao, Zhenyang and Chen, Binyan and Zhou, Jinghao and Jin, Jijie and Abramov, Dmitry and Chen, Shengzhang and Huang, Pan and Zhou, Jianghua},
  title = {Liver fibrosis biomarkers as a prognostic tool beyond the defining components in cardiovascular-kidney-metabolic syndrome},
  journal = {American Journal of Preventive Cardiology},
  year = {2026},
  volume = {26},
  pages = {101438},
  doi = {10.1016/j.ajpc.2026.101438}
}
Kostenlos starten →